ES2060927T3 - Anticuerpos contra la fibrina; peptidos inmunogenos adecuados para preparar los anticuerpos, metodo para determinar fibrina y preparacion farmaceutica basada en los anticuerpos. - Google Patents

Anticuerpos contra la fibrina; peptidos inmunogenos adecuados para preparar los anticuerpos, metodo para determinar fibrina y preparacion farmaceutica basada en los anticuerpos.

Info

Publication number
ES2060927T3
ES2060927T3 ES90201065T ES90201065T ES2060927T3 ES 2060927 T3 ES2060927 T3 ES 2060927T3 ES 90201065 T ES90201065 T ES 90201065T ES 90201065 T ES90201065 T ES 90201065T ES 2060927 T3 ES2060927 T3 ES 2060927T3
Authority
ES
Spain
Prior art keywords
fibrin
antibodies
pharmaceutical preparation
antibody based
determining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90201065T
Other languages
English (en)
Inventor
Willem Nieuwenhuizen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek TNO
Original Assignee
Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek TNO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek TNO filed Critical Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek TNO
Application granted granted Critical
Publication of ES2060927T3 publication Critical patent/ES2060927T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

ESTOS ANTICUERPOS ESTAN DIRIGIDOS CONTRA UNA SECUENCIA DE AMINO ACIDOS QUE CORRESPONDEN A LA SECUENCIA 311-379, EN PARTICULAR LA 311-336 DE LA CADENA DE FIBRINOGENO, LOS ANTICUERPOS REACCIONAN ESPECIFICAMENTE CON FIBRINA TANTO DEL TIPO I COMO DEL TIPO II, Y SON MUY EFECTIVOS PARA DETECTAR, PREVENIR Y TRATAR LA FORMACION DE COAGULOS DE SANGRE.
ES90201065T 1989-05-01 1990-04-26 Anticuerpos contra la fibrina; peptidos inmunogenos adecuados para preparar los anticuerpos, metodo para determinar fibrina y preparacion farmaceutica basada en los anticuerpos. Expired - Lifetime ES2060927T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL8901102A NL8901102A (nl) 1989-05-01 1989-05-01 Antilichamen tegen fibrine; voor de bereiding van de antilichamen geschikte immunogene peptiden, werkwijze voor het bepalen van fibrine en farmaceutisch preparaat op basis van de antilichamen.

Publications (1)

Publication Number Publication Date
ES2060927T3 true ES2060927T3 (es) 1994-12-01

Family

ID=19854590

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90201065T Expired - Lifetime ES2060927T3 (es) 1989-05-01 1990-04-26 Anticuerpos contra la fibrina; peptidos inmunogenos adecuados para preparar los anticuerpos, metodo para determinar fibrina y preparacion farmaceutica basada en los anticuerpos.

Country Status (8)

Country Link
US (1) US5124439A (es)
EP (1) EP0396188B1 (es)
JP (1) JP2634683B2 (es)
AT (1) ATE108833T1 (es)
DE (1) DE69010750T2 (es)
DK (1) DK0396188T3 (es)
ES (1) ES2060927T3 (es)
NL (1) NL8901102A (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009034A1 (en) * 1992-10-12 1994-04-28 Agen Limited Clot directed anticoagulant, process for making same and methods of use
DE69435072T2 (de) * 1993-11-02 2009-01-29 Mitsubishi Kagaku Iatron, Inc. Antikörper gegen menschliches lösliches fibrin, hybridome, die sie produzieren und immunmessverfahren
CA2188647A1 (en) * 1994-05-02 1995-11-09 Stewart Anthony Cederholm-Williams Recombinant fibrin chains, fibrin and fibrin-homologs
DE19729591A1 (de) * 1997-07-10 1999-02-11 Therasorb Medizinische Systeme Mittel zur Behandlung und/oder Prophylaxe von Mikrozirkulationsstörungen
US9814672B2 (en) 2007-03-09 2017-11-14 Susan T. Laing Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916070A (en) * 1986-04-14 1990-04-10 The General Hospital Corporation Fibrin-specific antibodies and method of screening for the antibodies
DE3701812A1 (de) * 1987-01-22 1988-08-04 Max Planck Gesellschaft Fibrinspezifischer antikoerper, verfahren zur seiner herstellung und seine verwendung

Also Published As

Publication number Publication date
DE69010750T2 (de) 1994-12-22
DE69010750D1 (de) 1994-08-25
JPH0348159A (ja) 1991-03-01
DK0396188T3 (da) 1994-08-22
EP0396188B1 (en) 1994-07-20
US5124439A (en) 1992-06-23
JP2634683B2 (ja) 1997-07-30
ATE108833T1 (de) 1994-08-15
EP0396188A1 (en) 1990-11-07
NL8901102A (nl) 1990-12-03

Similar Documents

Publication Publication Date Title
DK532284D0 (da) Fremgangsmaade til bestemmelse af antigenaktive aminosyresekvenser
DE3486030D1 (de) Monoklonale antikoerper, spezifisch von in vivo von fibrinogen abgeleiteten derivatstuecken.
EP0330506A3 (en) Vla proteins
DK0399666T3 (da) Fusionsproteiner indeholdende N-terminalfragmenter af human serumalbumin
DE69228701D1 (de) Fragmente von Prion Proteinen.
FI870447A0 (fi) Htlv-iii-hoeljepeptider.
NO831317L (no) Fremgangsmaate for fremstilling av funksjonelle menneske-urokinase proteiner.
ES2079621T3 (es) Procedimiento de identificacion o de titulacion de proteinas y aplicaciones.
DK163062C (da) Antigen, immunogen, proteinholdig vaccine imod coccidiose
DE68921229D1 (de) Prozess zur Behandlung von unlöslichem heterogenem Fusionsprotein.
ES2060927T3 (es) Anticuerpos contra la fibrina; peptidos inmunogenos adecuados para preparar los anticuerpos, metodo para determinar fibrina y preparacion farmaceutica basada en los anticuerpos.
ATE50458T1 (de) Bestimmung von fibrin mit fibrin-spezifischen antikoerpern.
SE8902148L (sv) Syntetiska peptid antigen foer detektion av htlv-1 infektion
DK213589D0 (da) Antistoffer mod fibrin og immunogen til brug ved fremstilling deraf
ATE137864T1 (de) Immunobestimmung von menschlichem osteocalcin, reagenz und satz dafür
DK0418590T3 (da) Antistoffer, fremstilling deraf og anvendelse deraf
JPS55141452A (en) Synthetic polypeptide
FI102381B1 (fi) Epstein-Barrin viruksen tuma-antigeeniin (EBNA) liittyviä synteettisiä polypeptidejä ja menetelmä anti-EBNA-vasta-aineiden tunnistamiseksi kudosnäytteessä
FR2601037B1 (fr) Peptide presentant des proprietes antigeniques isole de la proteine 28 kd de s. mansoni et son procede d'isolement, anticorps monoclonaux reconnaissant au moins un epitope dudit peptide et application de celui-ci dans l'induction de la synthese d'anticorps neutralisants
Chen Unique immunological cross-reactivity between fragments D and/or E of three heterologous mammalian fibrinogens
DE3485972D1 (de) Antigen aktive aminosaeuresequenzen.
ATE84318T1 (de) Monoklonale antikoerper, spezifisch von in vivo von fibrinogen abgeleiteten derivatstuecken.
Sobel et al. Immunochemical Studies of Aα Chain Crosslinking
GR1001087B (el) Μεθοδος και συστηματα για τον προσδιορισμο της παρουσιας ενος αντιγονου του pneumocystis carinii στο αιμα
ES492199A0 (es) Procedimiento para la obtencion de aminoacidos a partir de hidrolizados de proteinas

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 396188

Country of ref document: ES